Best Semaglutide Providers 2026: Editorial Ranking of Online & Telehealth Options

By the BestMedsHub Editorial Team. Last reviewed and updated May 2026. This guide is informational and does not constitute medical advice; semaglutide is a prescription medication and must be evaluated by a licensed clinician.

Semaglutide is the most clinically validated GLP-1 receptor agonist for chronic weight management on the U.S. market. It is the active ingredient in Novo Nordisk’s Wegovy (FDA-approved for obesity, 2021), Ozempic (FDA-approved for type 2 diabetes, 2017), and oral Rybelsus. Since 2023, a parallel market of compounded semaglutide telehealth providers has grown rapidly — and 2026 is the first full year operating under tightened FDA enforcement following the resolution of the Wegovy and Ozempic shortages.

This page ranks the providers we have independently evaluated against transparent criteria: pricing accuracy, FDA-approval status, dose flexibility, refund policy, and clinician access. Every price below was verified against the provider’s public-facing checkout flow during the May 2026 review window. Where a provider has shifted between brand-name and compounded supply, we note it explicitly.

Key takeaways (May 2026)

The STEP 1 trial (Wilding et al., NEJM 2021) showed an average 14.9% body-weight reduction at 68 weeks on semaglutide 2.4 mg vs 2.4% on placebo — the benchmark for setting realistic expectations.
The SELECT trial (Lincoff et al., NEJM 2023) demonstrated a 20% reduction in major adverse cardiovascular events in adults with overweight/obesity and pre-existing CV disease, independent of diabetes status.
Cash price for brand-name Wegovy in the U.S. remains roughly $1,349/month per Novo Nordisk’s list price, while compounded semaglutide from reputable telehealth networks typically lands between $159 and $299 per month.
Following the FDA’s October 2024 declaration that the semaglutide shortage was resolved, large-scale 503A compounding faces enforcement risk. Providers we rank acknowledge this transparently.
Our top-ranked provider for 2026 is Hims/Hers for combined regulatory posture, pricing transparency, and clinician oversight — but the “best” provider depends on whether you need an FDA-approved product, insurance coverage, or maximum out-of-pocket value.

What semaglutide is — clinical evidence summary

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to reduce appetite. The FDA approval history is the foundation of any honest “best provider” conversation:

2017 — Ozempic (subcutaneous semaglutide) approved for type 2 diabetes.
2019 — Rybelsus (oral semaglutide) approved for type 2 diabetes.
2021 — Wegovy (semaglutide 2.4 mg) approved for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity.
2022 — Wegovy approved for adolescents ≥12 years.
2024 — Wegovy label expanded to include reduction of major adverse cardiovascular events in adults with established CV disease and overweight/obesity, based on SELECT.

Three trial families anchor the evidence base:

STEP 1–5 trials (semaglutide 2.4 mg for obesity). STEP 1 reported 14.9% mean weight loss at 68 weeks; STEP 5 extended this to 104 weeks with sustained loss. STEP 3 added intensive behavioral therapy; STEP 4 examined withdrawal effects (most weight returned within a year of discontinuation, an important counseling point).
SUSTAIN 1–10 trials (Ozempic for type 2 diabetes). Established A1C reductions of 1.0–1.8% and modest weight loss vs comparators.
SELECT (2023). Roughly 17,600 patients without diabetes; 20% relative risk reduction in CV death, nonfatal MI, or nonfatal stroke over a median 39.8 months. Re-framed semaglutide as a cardiometabolic drug, not strictly a weight-loss drug.

For practical patient counseling, the most useful number remains the STEP 1 figure: expect roughly 14–15% body-weight loss at one year, with substantial individual variability, conditional on adherence and titration to the 2.4 mg maintenance dose.

How we ranked these semaglutide providers

Most “best semaglutide provider” lists you will find in 2026 are affiliate-driven and rank by commission, not by independent verification. We are an affiliate publisher too — see disclosure at the bottom of this page — but our ranking is anchored to criteria a reasonable patient would actually use. Our scoring weights are:

Pricing transparency (25%) — does the provider show a real monthly price before requiring an account or medical intake?
Regulatory posture (20%) — does the provider offer FDA-approved Wegovy/Ozempic, compounded only, or both? Is the regulatory status disclosed upfront?
Clinical oversight (15%) — is there an actual licensed clinician review, real follow-up, and access to messaging between visits?
Dose flexibility (15%) — can patients access the full titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) or are doses capped?
Refund and cancellation policy (10%) — does the provider offer a money-back guarantee or pro-rated refund?
Support quality (10%) — average response time, availability of clinician messaging, B12 add-ons, nutrition coaching.
State coverage (5%) — number of U.S. states served.

We did not accept payment for ranking placement. Where we earn an affiliate commission, the link is marked. Prices were captured between May 5–14, 2026, directly from each provider’s intake flow.

At-a-glance comparison table

Provider	Starting price/mo	FDA-approved option?	Max dose	B12 included?	Refund policy	Consult fee	States
Hims/Hers Weight Loss	$199	Yes (brand + compounded)	2.4 mg	Optional add-on	Pro-rated	$0	49
Ro Body	$229	Yes (Wegovy through Ro Pharmacy)	2.4 mg	No	Pro-rated	$99 intake	50
Henry Meds	$249	Compounded only	2.5 mg	Yes	30-day	$0	48
Remedy Meds	$159	Compounded only	2.5 mg	Yes	Limited	$0	47
Sequence (now Ro Body)	$229	Brand-name, insurance-first	2.4 mg	No	Monthly	$99	50
Calibrate	$199 (+ program fee)	Yes (insurance-routed)	2.4 mg	No	Pro-rated	Bundled	50
Found Health	$189	Yes (insurance preferred)	2.4 mg	Optional	30-day	$0	48
Mochi Health	$199	Both	2.4 mg	Optional	Pro-rated	$79	50
Medvi	$179	Compounded only	2.5 mg	Yes	30-day	$0	46

Prices verified May 2026. Compounded semaglutide availability is subject to FDA enforcement and state board rules; check current status at intake.

#1 Hims/Hers Weight Loss — best overall for 2026

Hims (men) and Hers (women) operate a single weight-loss platform with the most polished UX in the category and, importantly, both FDA-approved and compounded options. Plans start at roughly $199/month for compounded semaglutide on a quarterly autoship cadence; brand-name Wegovy is available where clinically appropriate at a separately disclosed price (typically routed through their pharmacy partner with documented insurance benefit checks).

Strengths: established brand and pharmacy infrastructure, transparent compounded pricing, full titration ladder up to 2.4 mg, in-app clinician messaging, and clear regulatory disclosures following the 2024–2025 FTC scrutiny of GLP-1 marketing claims.

Weaknesses: the lowest advertised price requires a quarterly subscription; autoship is harder to pause than at smaller providers; less flexibility on custom compounded ratios (e.g., semaglutide + B12 combinations).

Year-one out-of-pocket estimate: $199 × 12 = $2,388, plus optional add-ons. At the STEP 1 average of 14.9% loss for a 220 lb starting weight (~33 lb lost), that is roughly $72 per pound lost.

See Hims/Hers Weight Loss pricing (affiliate link)

#2 Ro Body — best for insurance-routed brand-name access

Ro Body (the rebranded Sequence program acquired by Ro) is the most credible path to brand-name Wegovy via insurance. The intake includes a $99 medical consult and an active benefits investigation. Out-of-pocket members pay roughly $229/month for the program plus medication cost. Where commercial insurance covers Wegovy, Ro will route the prior authorization.

Strengths: deep insurance navigation, in-house pharmacy, registered dietitian access, and the strongest clinician follow-up cadence in our review.

Weaknesses: the $99 intake fee is non-refundable; cash-pay patients pay more than at compounded-only providers.

#3 Henry Meds — strongest compounded option

Henry Meds is one of the longest-tenured compounded GLP-1 telehealth networks. Compounded semaglutide starts at $249/month with B12 included in the formulation, and dose escalation is straightforward up to a 2.5 mg equivalent.

Strengths: transparent compounded sourcing, fast clinician turnaround (often same-day), 30-day satisfaction policy, no consult fee.

Weaknesses: no FDA-approved option, so patients who later want Wegovy must transfer care; pricing is mid-pack rather than budget.

#4 Remedy Meds — best budget compounded option

Remedy Meds anchors the low end of the credible compounded market at roughly $159/month, with B12 included. Service is more transactional than at Hims or Ro, but the regulatory disclosures are clear and clinician availability is reasonable.

Read our full Remedy Meds review for dosing, sourcing, and intake details.

#5 Sequence (now Ro Body) — note the rebrand

Sequence, the Weight Watchers-acquired and then Ro-acquired clinical program, has been formally consolidated under Ro Body in 2025–2026. Existing Sequence members were migrated, and new sign-ups go through the Ro Body intake (see #2 above). We retain the line item here because the “Sequence semaglutide” query remains common.

#6 Calibrate — coaching plus medication

Calibrate bundles a one-year metabolic health program with medication (insurance-preferred). The program fee is the differentiator: patients who want structured one-on-one coaching and a defined curriculum get measurable value; patients who only want a prescription pay for coaching they may not use.

#7 Found Health — coaching-led, insurance-first

Found leads with insurance verification and a multi-disciplinary clinician pool that can also prescribe alternative agents (bupropion-naltrexone, metformin) where semaglutide is not appropriate. Compounded semaglutide is not their primary path. Best fit for patients who want flexibility on which medication is prescribed.

#8 Mochi Health — broad telehealth, both supply paths

Mochi offers both FDA-approved Wegovy (insurance-routed) and compounded semaglutide, with a $79 intake fee and roughly $199/month compounded pricing. State coverage is comprehensive. Clinician quality is variable based on the assigned provider.

#9 Medvi — newer entrant

Medvi is a 2024–2025 entrant focused on compounded GLP-1 access at roughly $179/month with B12 included. Smaller operation, fewer published reviews, but pricing and disclosures we reviewed were within normal ranges. Details in our Medvi review.

Real cost-per-pound-lost calculation

One number cuts through the marketing: dollars per pound lost. We apply the STEP 1 average of 14.9% body-weight reduction to a 220 lb reference patient (loss of ~32.8 lb at 68 weeks, or roughly 33 lb at 12 months for modeling purposes) and divide year-one out-of-pocket cost.

Brand-name Wegovy, cash price: $1,349 × 12 = $16,188 / 33 lb ≈ $490 per pound lost. At full list price without manufacturer savings card, the figure approaches $700/lb.
Hims/Hers compounded: $199 × 12 = $2,388 / 33 lb ≈ $72 per pound lost.
Henry Meds compounded: $249 × 12 = $2,988 / 33 lb ≈ $91 per pound lost.
Remedy Meds compounded: $159 × 12 = $1,908 / 33 lb ≈ $58 per pound lost.
Medvi compounded: $179 × 12 = $2,148 / 33 lb ≈ $65 per pound lost.
Wegovy with commercial insurance + savings card (typical eligible patient out-of-pocket $0–$25/mo for 12 months, then list price): year-one effective cost ranges from $0 to roughly $300 ($0–$10/lb), which is why Ro Body’s insurance-routing is competitive on a per-pound basis when coverage exists.

These calculations assume average response. Non-responders (roughly 10–15% in the STEP 1 cohort lost less than 5% body weight) will see much higher cost-per-pound figures regardless of provider.

Compounded vs FDA-approved semaglutide — what matters in 2026

Following the FDA’s October 2024 declaration that the semaglutide shortage was resolved, large-volume 503A compounding of semaglutide is no longer protected under the shortage exception. Enforcement has been uneven, and providers continue to operate under various legal interpretations. The practical implications for patients in May 2026:

Compounded semaglutide is not FDA-approved and not interchangeable with Wegovy or Ozempic from a regulatory standpoint, even when the API is identical.
Compounded products may include additional ingredients (commonly B12, occasionally L-carnitine) that have not been studied in the FDA semaglutide trials.
Patients who want the data-backed product specifically tested in STEP and SELECT should choose Wegovy/Ozempic.
Patients without insurance coverage who cannot afford brand-name and would otherwise go untreated may find compounded access medically reasonable when prescribed by a licensed clinician — a tradeoff to discuss with your provider, not a marketing claim.

For a deeper comparison, see our compounded vs brand-name semaglutide guide.

STEP trial benchmarks: what to expect

Weight loss trajectory: noticeable changes by week 8–12, peak loss around week 60–68. Plateau is normal and not a failure of the drug.
Side effects from STEP 1: nausea (~44%), diarrhea (~30%), vomiting (~24%), constipation (~24%) — most mild-to-moderate, mostly during titration. Serious gastrointestinal events were uncommon.
Discontinuation rate for adverse events in STEP 1: ~7%, vs ~3% on placebo.
Weight regain (STEP 4): roughly two-thirds of lost weight regained within one year of discontinuation. Plan for chronic therapy or aggressive behavioral consolidation.

Eligibility — who can get semaglutide

Per the Wegovy label, FDA-approved indications for chronic weight management are:

BMI ≥30 (obesity), or
BMI ≥27 (overweight) plus at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or established CV disease per the 2024 label expansion).

Contraindications (do not use):

Personal or family history of medullary thyroid carcinoma (MTC).
Multiple endocrine neoplasia syndrome type 2 (MEN 2).
Known serious hypersensitivity to semaglutide.
Pregnancy — discontinue at least 2 months before a planned pregnancy due to the long half-life.

Type 2 diabetes patients should generally use Ozempic (or Wegovy if obesity is the primary indication) rather than compounded semaglutide, because the FDA-approved products are the ones studied in the SUSTAIN trials.

How to switch providers if your first pick doesn’t fit

If your current provider raises prices, runs out of supply, or you simply want better clinician access, switching is usually straightforward — but dose continuity matters.

Request a copy of your current titration schedule (last dose, weeks at that dose) before cancelling. Most providers will email this on request.
Schedule the new provider’s intake before your final shipment runs out to avoid a gap. A gap longer than two weeks at maintenance doses often requires re-titration to avoid GI side effects.
If switching between compounded and brand-name (or vice versa), expect the new prescriber to confirm dose equivalence rather than match milligrams 1:1, particularly with compounded vials that may be dosed in units rather than mg.
Do not stack supplies across two providers — running parallel prescriptions creates duplicate-therapy flags on pharmacy records.

Frequently asked questions

Which provider has the cheapest semaglutide in 2026?
At the time of this May 2026 review, Remedy Meds at $159/month is the lowest credible advertised price for compounded semaglutide with B12. Medvi ($179) and Found Health (from $189) follow closely. Brand-name Wegovy is cheapest through insurance via Ro Body or Mochi when coverage is confirmed.

Are all semaglutide providers FDA-approved?
No. Only Wegovy (obesity) and Ozempic/Rybelsus (diabetes) are FDA-approved semaglutide products. Compounded semaglutide is dispensed under 503A/503B pharmacy rules and is not FDA-approved, even when the API is the same. Providers we rank disclose which supply path you are buying.

Can I get semaglutide with B12?
Yes, from most compounded providers — Henry Meds, Remedy Meds, and Medvi include B12 in the formulation by default. B12 is not part of the FDA-approved Wegovy or Ozempic formulations and is not required for semaglutide efficacy in the STEP trials.

Best semaglutide provider that takes insurance?
Ro Body has the most developed insurance workflow for Wegovy, followed by Calibrate and Found. Coverage depends on your plan’s formulary, your BMI, and any required step therapy. Expect prior authorization to take 1–3 weeks.

How does Hers compare to Henry Meds for semaglutide?
Hers is cheaper on the quarterly plan ($199 vs $249) and offers both FDA-approved and compounded paths. Henry Meds includes B12 and has a faster clinician turnaround. Pick Hers for brand and breadth; pick Henry Meds for compounding flexibility and 30-day satisfaction policy.

What’s the difference between Wegovy and compounded semaglutide?
Wegovy is the FDA-approved, Novo Nordisk-manufactured product studied in STEP and SELECT. Compounded semaglutide is prepared by a licensed compounding pharmacy from semaglutide sodium API; it is not FDA-approved and may include additional ingredients. Clinically, when dosed equivalently, response is typically similar — but the regulatory and quality-assurance frameworks differ.

Can I get semaglutide without a BMI of 30?
Yes, if your BMI is 27–29.9 and you have at least one weight-related comorbidity (hypertension, dyslipidemia, prediabetes, OSA, CV disease). Below BMI 27, most reputable providers will not prescribe semaglutide for weight management; this matches the Wegovy label.

Best semaglutide provider for diabetes patients?
Patients with type 2 diabetes should generally pursue Ozempic (the FDA-approved diabetes formulation) through their primary care or endocrinologist, with telehealth as a secondary channel. Ro Body and Found Health handle diabetes coding more rigorously than the cash-pay compounded shops; Calibrate is reasonable if you want bundled coaching.

Medical disclaimer

This page is for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Semaglutide is a prescription medication with contraindications and potential serious adverse effects. Do not start, stop, or change therapy without consulting a licensed clinician. If you experience symptoms of pancreatitis, gallbladder disease, severe gastrointestinal effects, or hypersensitivity reactions, seek medical care immediately.

Methodology disclosure

Rankings were determined by the criteria and weights described in the “How we ranked these semaglutide providers” section above. Pricing was captured directly from each provider’s public-facing intake flow between May 5 and May 14, 2026. Where a provider declined to display pricing pre-intake, we noted the consult fee separately. Clinical evidence cited above is drawn from peer-reviewed sources: Wilding JPH et al., NEJM 2021 (STEP 1); Lincoff AM et al., NEJM 2023 (SELECT); the Novo Nordisk Wegovy and Ozempic prescribing information; and the FDA approval history for semaglutide products.

Affiliate disclosure

BestMedsHub earns commissions on some of the provider links above (clearly marked as affiliate links). Commission rates did not influence ranking order. Providers cannot pay for placement, and we publish negative findings about advertisers where warranted. Our editorial standards and update cadence are documented on our About page.

Reviewed May 2026 by the BestMedsHub Editorial Team. Next scheduled review: November 2026, or sooner if FDA enforcement guidance, Novo Nordisk pricing, or major provider terms change.